DSIP
DSIP (Delta Sleep-Inducing Peptide)
A 9-amino acid neuropeptide that modulates sleep architecture, stress response, and cortisol secretion.
DSIP is not approved by the FDA for human use. It is sold strictly for research purposes only and is not intended for human consumption, diagnosis, treatment, or prevention of any disease or condition. Purchase and use is entirely at your own risk.
Sourcing for research purposes?
View at Ascension Peptides →What it is
Delta Sleep-Inducing Peptide (DSIP) is a 9-amino acid neuropeptide first isolated from rabbit brain in 1977 during studies on slow-wave (delta) sleep. It is found naturally in human plasma and CSF, with concentrations that vary with sleep-wake cycles.
Despite over four decades since its discovery, DSIP remains poorly understood mechanistically. Its receptor has not been definitively identified, and research results have been inconsistent — though a pattern of sleep-promoting and stress-modulating effects has emerged.
What research shows
- Promotion of slow-wave (delta) sleep in some studies — the sleep stage most associated with physical recovery
- Cortisol normalization — reported to reduce elevated cortisol without suppressing healthy levels
- Potential benefit in chronic pain and opiate withdrawal in some trials
- LH release stimulation — suggesting some gonadotropin axis involvement
- Antioxidant properties in some research
What remains unknown
- The receptor mechanism — no definitive DSIP receptor has been identified
- Consistency of sleep effects — research results have been mixed
- Optimal dosing and timing protocols
- Long-term safety profile
Administration basics
Common use cases
Sleep optimization, cortisol management, stress response modulation.
Half-life
Very short in plasma (~15 minutes). Effects may outlast plasma presence.
Administration
Subcutaneous injection or intranasal, typically taken 30–60 minutes before sleep.
Source this compound
Looking for DSIP?
Ascension Peptides is a third-party research compound vendor. We link to them as an affiliate — if you purchase through our link we may earn a commission at no cost to you. All compounds are sold for research purposes only and are not intended for human use.
View at Ascension PeptidesResearch Protocols & Common Usage
Doses used in research
- Research has used 25–50mcg/kg in studies
- Community protocols commonly report 100–500mcg per injection
Administration routes studied
Typical protocol duration
Short courses of 1–2 weeks are commonly reported in community use.
Common stacking protocols
- DSIP + Selank — combined for sleep quality and anxiolytic effects
- DSIP + Epithalon — combined in some longevity and sleep optimization protocols
Contraindications & combinations to avoid
- Benzodiazepines and Z-drugs — additive sedative effects; do not combine without physician oversight
- Alcohol and other CNS depressants — additive sedation risk
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with DSIP and what to avoid.
Track your DSIP protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the DSIP page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.